Baby GERMS Surveillance
Project

Baby GERMS is the first population-based surveillance programme on neonatal infections in Africa.

Baby GERMS Surveillance
Project

Baby GERMS is the first population-based surveillance programme on neonatal infections in Africa.

Project Overview

Project title: Baby GERMS Surveillance

Summary: Neonatal deaths account for almost half of deaths in children under 5 years, with infections being the third largest contributor after prematurity and intrapartum complications.

Lancet Global Health PMID: PMID 35839815

BMJ PMID: PMID 35135762

Project title: Baby GERMS Outbreak

Summary:

Despite major global progress in reducing under-five mortality, neonatal deaths remained high, accounting for nearly half of all child deaths. Infectious diseases were among the leading causes of neonatal mortality, particularly in sub-Saharan Africa, where reliable population-level data on neonatal infections had been scarce. In South Africa, existing studies were largely limited to tertiary hospitals, leaving major knowledge gaps in the true burden, causes, and antimicrobial resistance (AMR) patterns of neonatal infections across different healthcare levels. Accurate national data were essential to measure progress toward South Africa’s goal of reducing neonatal sepsis by 84% by 2025.

The Baby GERMS-SA study aimed to improve understanding of the incidence, aetiology, and outcomes of neonatal bloodstream infections (BSI) and meningitis in South Africa.

Its objectives were to:

  1. Determine the bacterial and fungal causes and incidence of culture-confirmed neonatal infections from 2014–2021.
  2. Describe the prevalence of AMR in neonatal pathogens at secondary-level hospitals.
  3. Identify clinical characteristics and modifiable risk factors associated with neonatal mortality.

A two-tiered surveillance approach was used:

  • Tier 1: Retrospective population-based surveillance of all culture-confirmed neonatal BSIs and meningitis in South Africa (2014–2021) using National Health Laboratory Service (NHLS) data to calculate provincial and facility-level incidence risks.
  • Tier 2: Prospective enhanced surveillance at six sentinel regional hospitals (one per province) to collect detailed clinical, epidemiological, and laboratory data to identify risk factors for mortality and characterise resistant pathogens.

A complementary national survey of neonatal units assessed staffing, diagnostic capacity, and infection-prevention practices to support interpretation of surveillance findings.

Outcomes and Impact

The project generated the first national dataset describing the burden and trends of neonatal infections and AMR across all healthcare levels in South Africa. Findings guided the Department of Health in designing targeted antimicrobial stewardship and infection-prevention programmes. Sentinel hospitals received facility-specific feedback to inform empiric treatment protocols and local quality-improvement interventions.

By providing robust baseline data on neonatal sepsis burden and resistance trends, Baby GERMS-SA strengthened surveillance capacity, enabled evaluation of national interventions, and contributed to achieving Sustainable Development Goal 3—improving neonatal and child health outcomes.

Key Objectives

Baby GERMS is the first population-based surveillance programme on neonatal infections in Africa and was set up in the latter half of 2019 with funding from the Bill and Melinda Gates Foundation (BMGF). The aim was to provide a baseline description of the aetiology, antimicrobial susceptibility and clinical characteristics of culture-confirmed neonatal bloodstream infections and meningitis in South Africa.

Through this surveillance programme, we aimed to identify modifiable risk factors which could be targeted to reduce neonatal morbidity and mortality. Baby GERMS has been acknowledged as a major new source of strategic data by the National Neonatal Task Force, which was launched in September 2019 to provide technical advice and guidance on surveillance for neonatal sepsis, infection prevention and control, neonatal infection case management, antimicrobialstewardship and containment of neonatal unit outbreaks.

In 2021, data from approximately 45 000 laboratory-confirmed cases of neonatal meningitis and blood stream infections were collated and analysed and a publication was submitted to Lancet Global Health. This analysis was shared with stakeholders from the National Department of Health to inform neonatal sepsis prevention guidelines.

Isolates collected from 933 episodes of laboratory-confirmed neonatal meningitis and blood stream infections occurring at 6 provincial/regional hospitals between October 2019 and September 2020 underwent further genotypic and phenotypic analysis and results on the numerous Klebsiella pneumoniae infections have been shared with KlebNET, an international group looking at global genomics of Klebsiella K-loci.

Aspects of the sentinel surveillance data were shared at the International Symposium on Streptococcus Agalactiae Disease (ISSAD) and the World Symposium on Paediatric Infectious Diseases (WSPID).

Partners

Team Members

  • Prof. Nelesh Govender
  • Susan Meiring
  • Vanessa Quan
  • Rudzani Mashau
  • Rindidzani Magobo
  • Olga Perovic
  • Linda de Gouveia
  • Cheryl Mackay
  • Rose Phayane
  • Marshagne Smith
  • Sibongile Walaza
  • Mphekwa Thomas Mailula
  • Angela Dramowski
  • Ruth Mpembe
  • Cheryl Cohen
  • Omphile Mekgoe
  • Anne von Gottberg
  • Constance Kapongo
  • Lerato Motjale

Publications

Media